AARTI DRUGS LIMITED

AARTIDRUGS

Sector: PharmaceuticalsSub-sector: Active Pharmaceutical Ingredients (APIs)
Qtr Score Rank 53 / 57 (Top 9 percentile)Growth Score Rank: Not ranked

Quarterly Score

↔ Trend: Stable
Sentiment stable - Recent avg: 6.90, Historical avg: 7.00

Showing the latest 12 quarterly points (newest to oldest).

Score context (latest 12 quarters)

Q1FY25
6.5

No additional context available.

Q2FY25
5.5

No additional context available.

Q3FY25
7.5

No additional context available.

Q4FY25
8.5

No additional context available.

Q1FY26
7.5

No additional context available.

Q2 FY2026
7.2

Management expects high single-digit value growth for H2 FY26. Long-term EBITDA margin target is 15-16%, with a run-rate of 15% targeted by H2 FY27 based on Salicylic Acid ramp-up and Sayakha integration.

Quarter summary

  • Strategic shift towards complete backward integration for the Metformin chain via the new Sayakha facility to insulate against raw material volatility.
  • Stabilization of the Salicylic Acid project with market acceptance of quality now achieved; focus shifting to cost optimization and volume ramp-up to reach the 800 TPM EBITDA break-even point.

Rationale

  • EBITDA margins expanded 150 bps YoY to 12.9% (Consolidated) despite absorbing ~Rs. 3.5 crores in losses from the Salicylic acid plant and initial start-up costs at the Sayakha facility.
  • Strong balance sheet management with net debt reducing by Rs. 41 crores in H1 FY26 to Rs. 571 crores, resulting in a record low debt-to-equity ratio of 0.39.
Q3 FY2026Latest
6.0

Management expects 12% to 15% volume growth in FY27, driven by the push of delayed FY26 growth into the next fiscal year. EBITDA margins are targeted to recover to 12-13% in the near term and 14-15% in steady-state operations once new plants stabilize.

Quarter summary

  • The company is in a transition phase, shifting from heavy capital expenditure to an operational scale-up phase for its new backward integration facilities.
  • Formulations strategy is pivoting toward niche, higher-value offerings including a dedicated US FDA-approved oncology site with commercialization expected in Q4 FY26.

Rationale

  • Consolidated EBITDA margins contracted to 9.3% in Q3 FY26 from ~12.9% in Q2, driven by a combined EBITDA drag of ₹8.5 Cr from the Sayakha and Salicylic acid facilities and 1% gross margin pressure from selling through existing inventory (₹30 Cr FG stock sale).
  • Positive volume momentum is evident with a 7% YoY volume growth in the standalone segment, offsetting a 5% negative rate variance, while the high-margin Formulations business grew 58% YoY (₹76.6 Cr) driven by exports.

Future Growth Prospects

Growth outlook data not available yet for this company.

Story of the Stock - Top Strategies

Latest Fiscal Years: FY26, FY25, FY24Top strategies (ranks 1-3) per year
Curated from latest transcripts
Fiscal YearFY26
#1Impact: HIGH

Backward Integration & Capacity Expansion

Capex of Rs. 600 crores underway to boost capacity, margins, and drive revenue growth, with Rs. 150-200 crores planned for FY26.

Sayakha plant commenced trial production; Salicylic acid plant targeting 500 tonnes/month by Q4 FY26; FY26 capex Rs. 150-200 Cr.
Show more

Focus on backward integration and capacity expansion through greenfield projects (Sayakha, Tarapur) and brownfield expansions to enhance raw material security, improve cost competitiveness, and drive revenue growth.

Impact: 600 Cr

Evidence

Capex of Rs. 600 crores underway, starting from FY22 for the next 4-5 years.
Sayakha plant commenced trial production, expected to contribute meaningfully to profitability.
Salicylic acid plant at Tarapur targeting a cumulative capacity of ~1,600 tonnes per month by the end of 2025-26.
FY26 capex estimated at Rs. 150-200 crores.
#2Impact: HIGH

Focus on Regulated Markets & Exports

USFDA approval for Tarapur API facility and EU certifications enable higher-value exports, contributing to improved margins and market access.

USFDA approval received; EU certifications obtained; targeting regulated market growth from FY27 onwards.
Show more

Leveraging USFDA and EU certifications to increase exports to regulated markets, which offer superior margins and higher selling prices.

Evidence

USFDA approval for Tarapur API facility allows resumption of exports to the US market.
EU certifications from larger plants enable shifting high-value exports to lower-cost platforms, improving margin capture.
Regulated market sales will lead to higher selling prices and better gross margins.
Expects to launch 3 products in the USFDA market within 9-12 months.
#3Impact: HIGH

Product Portfolio Expansion & R&D

Developing and launching new products, including complex generics and new age molecules, to drive revenue growth and market penetration.

Targeting launch of 2-3 key products in US/Europe in next 6-9 months; Oncology dossiers development ongoing.
Show more

Expanding the product portfolio through R&D, focusing on new age molecules for regulated markets and complex generics, which are expected to contribute to future growth.

Evidence

Developing complex APIs and formulations for regulated markets like the US and Europe.
Expecting to commercialize first product in US (Bicalutamide) this quarter and anti-diabetic products in Europe/UK in next 6-9 months.
New products combined should give an additional top line of Rs. 60-70 crores.
Strong pipeline of products under R&D for future growth.
Fiscal YearFY25
#1Impact: HIGH

US FDA Approval and Export Expansion

US FDA approval for API facility enables exports to US market, expecting 30+ EBITDA margins.

Production for US market expected to commence post-approval, with meaningful contribution from FY'27.
Show more

The company received US FDA approval for its API manufacturing facility, opening up exports to the US market. This is expected to significantly improve margins.

Impact: 30 %

Evidence

"We are pleased to announce that Aarti Drugs has recently received approval following a successful inspection by the US FDA plant -- by the US FDA authorities at its API manufacturing facility..."
"In fact, when US FDA import alert struck us, the product, which we were selling in the US market through this facility was having EBITDA in almost, you can say late 30s EBITDA margin. So we can at least expect 30-plus EBITDA margins coming from this facility."
"So the first market, I think, which shall open up should be the European markets for us... and then US markets as well. But as you correctly pointed out that because this is a highly regulated market, the gestation period is higher. So the meaningful contribution may not come from FY '26 itself. Probably it will start flowing-in in FY '27."
#2Impact: HIGH

Greenfield Project for Specialty Chemicals

Greenfield project at Sayakha, Gujarat for Specialty Chemicals to commence trial production, expected to improve gross margins.

Trial production expected in February, with operating leverage kicking in from the subsequent quarter.
Show more

The company's greenfield project at Sayakha, Gujarat for Specialty Chemicals is on track and expected to commence trial production, contributing to operating leverage and improved gross margins.

Evidence

"Now coming back to API segment, the greenfield project at Sayakha, Gujarat for Specialty Chemicals, which is also related to the backward integration, will commence trial production in this quarter, most probably in the month of February itself."
"With this, the operating leverage is expected to kick in from the subsequent quarter with improved capacity utilization. This will also help us in improving our gross margins."
#3Impact: LOW

Solar Power Plant Initiative

Acquisition of 26.25% equity stake in a SPV for a solar power plant, expected to save INR 3.6 Cr annually and reduce CO2 emissions.

Expected to commence operations by end of H1 FY'26.
Show more

Aarti Drugs has entered into an agreement to acquire a stake in a Special Purpose Vehicle (SPV) for a solar power plant, aimed at captive consumption. This initiative aligns with the company's commitment to green energy and cost optimization.

Impact: 3.6 Cr

Evidence

"Additionally, we are excited to share that Aarti Drugs has entered into a share subscription and shareholders agreement with Prozeal Green Power Private Limited and Pro-Zeal Green Power Six Private Limited a special purpose vehicle."
"This solar plant will give us approximately 8.9 million renewable units per annum, and it is expected to commence the operation by end of H1 FY '26. This can result to a full year annual saving of around INR3.6 crores for our Gujarat plant."
"This initiative will reduce around 1,000 tons of carbon dioxide emissions due to use of renewable energy."
Fiscal YearFY24
#1Impact: HIGH

Capacity Expansion and New Product Launches

Capex of Rs. 600 crores underway to drive revenue potential of Rs. 4,200-4,500 crores with higher margins in next 5-6 years

Capex underway from FY22 for next 4-5 years; full ramp-up expected in 5-6 years.
Show more

The company is investing in capacity expansion and new product development across API and formulation segments, aiming to drive significant revenue growth and margin improvement.

Impact: 4200 Cr

Evidence

Capex of Rs. 600 crores underway [starting from FY22 for the next 4-5 years]
Revenue potential: Rs. 4,200 – 4,500 crores with higher margin profile in next 5-6 years
New capacities established since last two years will help grow top-line.
#2Impact: HIGH

Backward Integration

Backward integration for API and Formulation segments to drive cost synergies and improve margins

Expected to drive margins over the next 5 years.
Show more

The company is focusing on backward integration to achieve cost synergies, which is expected to lead to robust expansion in margins and return ratios.

Evidence

Backward integration for the API and Formulation segments to drive cost synergies
Robust expansion in margins and return ratios is expected through backward integration over next 5 years
Exploring backward integration options for Anti Diabetic products.
#3Impact: HIGH

Focus on Specialty Chemicals and Formulations

Targeting high growth in Specialty Chemicals and increasing contribution from Formulation segment

Specialty chemical business expected to double once capacities come up; Formulation exports expected to grow.
Show more

The company is focusing on expanding its specialty chemicals business and increasing the contribution of its formulation segment, particularly in export markets.

Evidence

Focus on increasing contribution from Speciality Chemicals, Intermediates & Others, going forward
In the formulation business, we foresee a consistent rate of growth in exports.
Specialty chemicals grew about 38%, year-on-year for FY '23.

Business Segments

Community

Share your view anonymously. Comments are public and sorted newest first.

Anonymous post · 1500 characters left

Loading comments...